^
Association details:
| Biomarker: | TMB-H + PD-L1 underexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review
Published date:
08/27/2021
Excerpt:
Here, we reported a Chinese patient with pancreatic cancer, a high TMB and low expression of PD-L1 who responded well to the combined therapy of pembrolizumab and chemotherapy.
Secondary therapy:
Chemotherapy
DOI:
10.1097/CAD.0000000000001232
